Advertisement
Advertisement
TOPIC

Innovent Biologics

(信达生物)

Innovent Biologics
信达生物
Established in 2011, Innovent Biologics is a biotechnology company that develops, manufactures and commercialises medicine for oncology, cardiovascular and metabolic diseases, autoimmune diseases and ophthalmology. The Suzhou-headquartered company was listed on the Hong Kong stock exchange on October 31, 2018.
Biomedicine: Companies

China’s Innovent Biologics signs US$10.5b Pfizer deal for 12 cancer drug trials

The agreement covers eight early-stage trials from Innovent and four discovery programmes from global giant Pfizer.

videocam

China’s pharmaceutical industry transforms into a global innovation powerhouse

XtalPi’s 615% jump in drug revenue highlights China’s biotech boom

First payment from US$6 billion deal with Gregory Verdine’s DoveTree swings the Hong Kong-listed firm to a net profit.

Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement